RBP Global Holdings

RBP Global Holdings Limited is a specialized pharmaceutical intermediate holding and treasury company within the Indivior Group, a global leader in the treatment of substance use disorders (SUD) and serious mental illness. Originally formed as the pharmaceutical arm of Reckitt Benckiser (RB Pharmaceuticals), the company was established as a stand-alone entity following the 2014 demerger that created Indivior PLC. The company's operations focus on a high-value portfolio of buprenorphine-based therapies, including the market-leading long-acting injectable Sublocade and the sublingual film Suboxone, which are gold standards for treating opioid use disorder (OUD). In addition to its commercial products, RBP Global Holdings supports a clinical pipeline targeting unmet needs in addiction, featuring novel mechanisms such as orexin-1 receptor antagonism and extended-release prodrug technologies. Based in Slough, UK, the company manages the group’s financial strategies and holds various corporate debt instruments listed on The International Stock Exchange (TISE).